These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11137322)

  • 1. Phthalic acid mimics 17beta-estradiol actions in WISH cells.
    Pavan B; Biondi C; Ferretti ME; Lunghi L; Paganetto G
    Toxicol Lett; 2001 Jan; 118(3):157-64. PubMed ID: 11137322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17beta-estradiol modulates prostaglandin E2 release from human amnion-derived wish cells.
    Pavan B; Biondi C; Ferretti ME; Lunghi L; Paganetto G
    Biol Reprod; 2001 Jun; 64(6):1677-81. PubMed ID: 11369594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
    Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
    Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17Beta-eEstradiol stimulates arachidonate release from human amnion-like WISH cells through a rapid mechanism involving a membrane receptor.
    Fiorini S; Ferretti ME; Biondi C; Pavan B; Lunghi L; Paganetto G; Abelli L
    Endocrinology; 2003 Aug; 144(8):3359-67. PubMed ID: 12865314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of oxytocin on prostaglandin E2, intracellular calcium, and cyclic adenosine monophosphate in human amnion-derived (WISH) cells.
    Pavan B; Buzzi M; Ginanni-Corradini F; Ferretti ME; Vesce F; Biondi C
    Am J Obstet Gynecol; 2000 Jul; 183(1):76-82. PubMed ID: 10920312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
    Cherry JA; Thompson BE; Pho V
    Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role of intracellular cyclic AMP levels.
    Ottonello L; Gonella R; Dapino P; Sacchetti C; Dallegri F
    Exp Hematol; 1998 Aug; 26(9):895-902. PubMed ID: 9694511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain.
    Schwabe U; Miyake M; Ohga Y; Daly JW
    Mol Pharmacol; 1976 Nov; 12(6):900-10. PubMed ID: 187926
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective inhibitors of specific phosphodiesterases in intact adipocytes.
    Manganiello V; Degerman E; Elks M
    Methods Enzymol; 1988; 159():504-20. PubMed ID: 2457789
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
    Zhu WH; Majluf-Cruz A; Omburo GA
    Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells.
    Chang YH; Conti M; Lee YC; Lai HL; Ching YH; Chern Y
    J Neurochem; 1997 Sep; 69(3):1300-9. PubMed ID: 9282956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
    Souness JE; Hassall GA; Parrott DP
    Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of 3',5'-nucleotide phosphodiesterase and the stimulation of cerebral cyclic AMP formation by biogenic amines in vitro and in vivo.
    Nahorski SR; Rogers KJ
    Neuropharmacology; 1976 Oct; 15(10):609-12. PubMed ID: 186725
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
    Elks ML; Manganiello VC
    Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
    Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
    J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
    Némoz G; Prigent AF; Picq M; Pacheco H
    Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
    [No Abstract]   [Full Text] [Related]  

  • 18. Morphone abstinence and quasi-abstinence effects after phosphodiesterase inhibitors and naloxone.
    Francis DL; Roy AC; Collier HO
    Life Sci; 1975 Jun; 16(12):1901-6. PubMed ID: 168452
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogenic activity and metabolism of n-butyl benzyl phthalate in vitro: identification of the active molecule(s).
    Picard K; Lhuguenot JC; Lavier-Canivenc MC; Chagnon MC
    Toxicol Appl Pharmacol; 2001 Apr; 172(2):108-18. PubMed ID: 11298497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.